Form 4: Catherine Moukheibir Acquires Options in MoonLake Immunotherapeutics
SEC Form 4 Filing
Director Catherine Moukheibir acquired options to purchase 7,688 Class A Ordinary Shares of MoonLake Immunotherapeutics on June 6, 2024.
Summary
- On June 6, 2024, Catherine Moukheibir, a director of MoonLake Immunotherapeutics, acquired options to purchase 7,688 Class A Ordinary Shares.
- The exercise price of the options is $42.44.
- The options vest in full on the earlier of June 6, 2025, the date of the Issuer's next annual general meeting of shareholders, or the date of a Change in Control of the Issuer, subject to continued service.
- The options expire on June 6, 2034.
Sentiment
Score: 5
Explanation: The document is a standard SEC Form 4 filing, indicating a routine transaction. It doesn't inherently convey positive or negative sentiment.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.
Key Dates
| Date | Description |
|---|---|
| 06/06/2024 | Date of transaction: Catherine Moukheibir acquired options to buy 7,688 shares. |
| 06/06/2024 | Option exercise price is $42.44. |
| 06/06/2025 | Earliest vesting date for the options. |
| 06/07/2024 | Date of signature for the Form 4 filing. |
| 06/06/2034 | Expiration date of the options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.